FeesSafety
Pluang+

JYP terminates Xdinary Heroes leader Gunil over fan misconduct allegations.

Market News
13 Aug 2026
Forbes
View Source
Bearish
JYP terminates Xdinary Heroes leader Gunil over fan misconduct allegations.

JYP Entertainment has terminated drummer and leader Gunil's contract and removed him from the K-rock group Xdinary Heroes following online allegations of misconduct towards fans. The band will continue as a five-member group. The allegations, made by an individual claiming to be Gunil's former girlfriend, accused him of privately insulting fans, though these claims remain unverified. This swift action reflects a broader trend in the K-Pop industry of rapid responses to reputational risks amid a turbulent year marked by multiple artist departures.

More News

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...

Market News
Bullish
2 hours ago
CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...

Market News
Bullish
2 hours ago
CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...

Market News
Bullish
2 hours ago
Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...

Market News
Bullish
2 hours ago
Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App